Treatment characteristics and resultsa
| No. of Treatment Procedures | |
|---|---|
| Total No. of sessions | 50 |
| 1 session per DAVF | 37 (86.1%) |
| 2 sessions per DAVF | 5 (11.6%) |
| 3 sessions per DAVF | 1 (2.3%) |
| No. of arteries embolized per session | |
| 1 | 22 (44%) |
| 2 | 25 (50%) |
| 3 | 3 (6%) |
| Embolized arteryb | |
| Middle meningeal | 42 (51.9%) |
| Occipital | 35 (43.2%) |
| Superficial temporal | 3 (3.7%) |
| Ascending pharyngeal | 1 (1.2%) |
| Volume of NALEA injected per pedicle (mL) | |
| Middle meningeal | 4.48 (0.8–13.4) |
| Occipital | 4.53 (0.7–15.6) |
| Duration of NALEA injection per pedicle (min) | |
| Middle meningeal | 33.4 (8–110) |
| Occipital | 27.3 (8–62) |
| Treatment approach per DAVF | |
| Arterial | 42 (97.7%) |
| Arterial + venous | 1 (2.3%) |
| Balloon use per session | |
| Only transarterial | 20 (40%) |
| Only transvenous | 1 (2%) |
| Transarterial + transvenous | 21 (42%) |
| None | 8 (16%) |
| Angiographic outcome | |
| Immediate total occlusion | 39/43 (90.7%) |
| 6-Month total occlusion | 40/41 (97.6%) |
| Clinical outcome | |
| Asymptomatic | 32 (78.1%) |
| Improvement of symptoms | 7 (17.1%) |
| Worsening of symptoms | 1 (2.4%) |
| Death | 1 (2.4%) |
| Complications | |
| Facial palsy | 2 |
| Cerebellar ischemia | 1 |
| Alopecia | 1 |
| Scalp necrosis | 1 |